Immunoproteins refers to proteins like immunoglobulin, haptoglobin and pre-alubumin that are found in the blood and regulate the body’s immune responses. The testing of immunoproteins is hence aimed at diagnosing health conditions that get revealed by abnormal immunoprotein activity. Certain health conditions that can be revealed through immunoprotein activity include cardiovascular diseases, cancers, diabetes, obesity, rheumatoid arthritis and infectious diseases such as tuberculosis, malaria and AIDS.
The competition landscape in the immunoprotein diagnostic testing market is moderately fragmented as several companies operate in the market. It is however also very complex since there are some companies that cater to all type-based, technology-based and application -based segments, while others who specialise in one of the segments, while still others specialise in certain products found in one or more segments.
This diversity in the competition landscape translates into firms targeting mergers and acquisitions, strategic partnerships and joint ventures to expand their market share. New and innovative product launches are also a frequent marketing strategy adopted by manufacturers.
For example, Eurobio Scientific is reportedly in negotiations with Vivo Medical for acquisition of Pathway Diagnostics and Personal Diagnostics to expand its market share in UK and Ireland. Notably, Eurobio Scientific is itself the result of ExonHit’s 2012 acquisition of Ingen and later acquisition of Eurobio in 2017.
Other recent acquisitions include Meridian Bioscience’s acquisition of GenoPic, which operates the popular Revogene molecular diagnostics platform that offers flexible testing capabilities and multiplexing. Similarly, DiaSorin has acquired Focus Diagnostics and its immunodiagnostic and molecular diagnostic brands HerpeSelect and HSV Serolog.
Meanwhile, Ortho Clinical Diagnostics and Beckman Coulter have inked a strategic partnership to boost US sales of Ortho’s VITROS 3600 Immunodiagnostic System. In terms of new product launches, an example is DiaSorin’s new serological assay, christened LIAISON H. pylori IgG, which when combined with the LIAISON Analyzer is believed to offer a 90.4 to 98.4 percent range of accurate results.
A key trend in research and launch of new products is that technologies have proven ill-effects on personal health are being phased out in favour of newer technologies. For example, chemiluminescence assays have seen a rapid growth in recent years, even as radioimmuno assays have seen a steady decline. This is in large part due to changing government regulations as well.
Some of the key players in the market include Diasorin, Abbott Laboratories, Beckman Coulter, Fujirebio Diagnostics, Abcam PLC, AdnaGen, Bio-Rad Laboratories, Eurobio Scientific, Agilent Technologies, Danaher Corporation, Meridian Bioscience, A. Menarini Diagnostics, Randox Laboratories, Enzo Life Sciences, BioMerieux, Ortho Clinical Diagnostics, F. Hoffmann-La Roche Diagnostics, Adaltis, Siemens Healthcare, The Binding Site, Affymetrix and Thermo Fisher Scientific.
Drivers and Constraints of the Immunoprotein Diagnostic Testing Market
Increasing instances of infectious diseases and lifestyle-induced health conditions has been the leading driver for the immunoprotein diagnostic testing market. The rising population of elderly persons and increasing access to advanced healthcare facilities has further contributed to market growth.
However, the market faces constraints due to stringent government norms in several developed countries over approval of immunoprotein diagnostic testing methods and products. Availability to cheaper testing alternatives due to lax application of intellectual property rights in certain developing countries is also a major challenge for the market.
Impact of Covid-19
The lockdowns instituted due to the Covid-19 pandemic has affected several companies, especially supply chain procedures. However, the long-term impact of the Covid-19 crisis on the market is likely to be positive as early diagnosis and prevention of health conditions will find a favourable response owing to increased sensitivity towards public health and healthcare.
The North American regional segment has occupied a dominant position in the market due to fewer constraints and a strong influence of market drivers. This is expected to continue during the forecast period as well. The European regional segment is the second largest segment for the market.
The East Asian regional segment has seen substantial growth in recent years, mainly led by the developed counties in maritime East Asia. South Asia is another growing segment due to increased accessibility to healthcare in the region’s developing economies, but this segment faces strong constraints. Latin America, Oceania and Middle East and Africa are the other key regional segments.
The immunoprotein diagnostic testing market can be segmented based on the following:
The report covers exhaustive analysis on:
Regional analysis includes
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.